Search

Displaying results 2611 - 2620 of 4234 in total
  1. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis).

  2. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skele...

  3. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    One minor metabolite, the isoprene, has the same potency as its parent compound.

  4. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    [L6163] Currently, triamterene is used in the treatment of edema associated with various conditions as monotherapy and is approved for use with other diuretics to enhance diuretic and potassium-sparing

  5. Drug

    Pegloxenatide

    go.drugbank.com/drugs/DB19230
    Investigational

    Pegloxenatide is under investigation in clinical trial NCT05172999 (Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia).

  6. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.

    Synonyms: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.
  7. Drug

    Hydrocortisone butyrate

    go.drugbank.com/drugs/DB14540
    ApprovedVet approved

  8. Drug

    Hydrocortisone probutate

    go.drugbank.com/drugs/DB14543
    ApprovedVet approved

  9. Drug

    Prothrombin

    go.drugbank.com/drugs/DB11311
    ApprovedInvestigational

    Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.

  10. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant. … [A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational